IL115224A0 - Preparations for use in the treatment of osteoporosis - Google Patents

Preparations for use in the treatment of osteoporosis

Info

Publication number
IL115224A0
IL115224A0 IL11522495A IL11522495A IL115224A0 IL 115224 A0 IL115224 A0 IL 115224A0 IL 11522495 A IL11522495 A IL 11522495A IL 11522495 A IL11522495 A IL 11522495A IL 115224 A0 IL115224 A0 IL 115224A0
Authority
IL
Israel
Prior art keywords
osteoporosis
preparations
treatment
Prior art date
Application number
IL11522495A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL115224A0 publication Critical patent/IL115224A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11522495A 1994-09-09 1995-09-08 Preparations for use in the treatment of osteoporosis IL115224A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30392594A 1994-09-09 1994-09-09

Publications (1)

Publication Number Publication Date
IL115224A0 true IL115224A0 (en) 1995-12-31

Family

ID=23174289

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11522495A IL115224A0 (en) 1994-09-09 1995-09-08 Preparations for use in the treatment of osteoporosis

Country Status (8)

Country Link
EP (1) EP0779812A4 (xx)
JP (1) JPH10505090A (xx)
KR (1) KR970705400A (xx)
CN (1) CN1157565A (xx)
AU (1) AU686458B2 (xx)
CA (1) CA2199252A1 (xx)
IL (1) IL115224A0 (xx)
WO (1) WO1996007417A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
JP2009515535A (ja) 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4868164A (en) * 1986-12-19 1989-09-19 Norwich Eaton Pharmaceuticals, Inc. Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
US5403824A (en) * 1993-03-19 1995-04-04 The Procter & Gamble Company Methods for the treatment of osteoporosis

Also Published As

Publication number Publication date
EP0779812A4 (en) 1997-09-10
AU3547595A (en) 1996-03-27
CN1157565A (zh) 1997-08-20
JPH10505090A (ja) 1998-05-19
KR970705400A (ko) 1997-10-09
EP0779812A1 (en) 1997-06-25
WO1996007417A1 (en) 1996-03-14
CA2199252A1 (en) 1996-03-14
AU686458B2 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
EG24222A (en) Spiro-azabicyclic compounds useful in therapy
GB9407135D0 (en) Treatment of osteoporosis
SG99279A1 (en) Myoblast therapy for cosmetic treatment
GB9411080D0 (en) Treatment
ZA952356B (en) Skin treatment composition
GB9423868D0 (en) Compounds for use in medicine
GB9402641D0 (en) Therapeutic agents
GB9416467D0 (en) Compounds for use in medicine
GB9414157D0 (en) Medical use
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
GB9424694D0 (en) Compounds for use in medicine
GB9405021D0 (en) Skin treatment composition
IL115225A0 (en) Preparations containing estrogen compounds for use in the treatment of osteoporosis
IL115223A0 (en) Preparation containing antiresorptive compounds for use in the treatment of osteoporosis
GB9401879D0 (en) Therapeutic agents
GB9405046D0 (en) Skin treatment composition
GB9219776D0 (en) New compounds for use in the treatment of cancer
ZA951420B (en) Therapeutic agents
GB9625449D0 (en) Compounds for use in medicine
GB9411244D0 (en) Compounds useful in therapy
ZA957122B (en) Spiro-azabicyclic compounds useful in therapy
GB9422497D0 (en) Compounds useful in therapy
BG99140U (en) Preparation for hair treatment
GB9411774D0 (en) Surgical dressing
GB9504627D0 (en) Compounds for use in therapy